Apixaban for the prevention of venous thromboembolism in people ...

More documents

Recommendations

Info

Figure 5.8 Cost-effectiveness acceptability curve for apixaban versus rivaroxaban in TKR (Fig 13 MS-Appendix 23) Comment – In the original model only two treatments could be compared at once. This means that a probabilistic sensitivity analysis for all four comparators was not possible. The ERG requested a full incremental analysis in the clarification letter, which was then provided. The adapted PSA showed that in THR, apixaban had a 53% probability of being the most cost-effective drug at a threshold of £20,000 per QALY (Figure 5.9). Rivaroxaban had a probability of 47%. At a threshold of £30,000 these probabilities were 47% and 53%, respectively. For TKR, a threshold of £20,000 apixaban had a 11% probability of being the most cost-effective drug. For rivaroxaban this probability was 89%. At a threshold of £30,000 these probabilities were 10% and 90%, respectively. The cost-effectiveness acceptability curves including all four comparators are presented in Figure 5.9 (THR) and 5.10 (TKR). 62 Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.
Cost-Effectiveness Acceptability Curve Figure 5.9 Cost-effectiveness acceptability curve for apixaban, enoxaparin, dabigatran and rivaroxaban in THR (manufacturer’s response to clarification letter, Figure 3) Probability of cost-effectiveness 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 0 5000 10000 15000 20000 63 25000 Willingness to pay Cost-Effectiveness Acceptability Curve 30000 35000 40000 Enoxaparin 40 mg Apixaban Rivaroxaban Dabigatran Figure 5.10 Cost-effectiveness acceptability curve for apixaban, enoxaparin, dabigatran and rivaroxaban in TKR (manufacturer’s response to clarification letter, Figure 4) Probability of cost-effectiveness 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 0 5000 10000 15000 20000 25000 Willingness to pay 30000 35000 40000 Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved. 45000 45000 50000 Enoxaparin 40 mg Apixaban Rivaroxaban Dabigatran 50000
Page 1 and 2:
in collaboration with: Apixaban for
Page 3 and 4:
Abbreviations AAOS American Academy
Page 5 and 6:
1. SUMMARY ........................
Page 7 and 8:
1. SUMMARY 1.1 Scope of the manufac
Page 9 and 10:
The three identified trials, which
Page 11 and 12: Table 2.1. Summary of Annual TKR an
Page 13 and 14: The NICE clinical guideline on redu
Page 15 and 16: Indirect and mixed treatment compar
Page 17 and 18: 4.1.2 State the inclusion/exclusion
Page 19 and 20: APROPOS 2 0 Phase II, randomised, e
Page 21 and 22: 4.2 Summary and critique of submitt
Page 23 and 24: Table 4.5: Results for Apixaban ver
Page 25 and 26: Trial no. (acronym) ADVANCE 1 ADVAN
Page 27 and 28: 4.2.4 Describe and critique the man
Page 29 and 30: Table 4.9: Results from indirect co
Page 31 and 32: Results for the main outcomes from
Page 33 and 34: 5 COST EFFECTIVENESS 5.1 ERG commen
Page 35 and 36: Table 5.1 Main findings of studies
Page 37 and 38: 5.2.2 Model structure The manufactu
Page 39 and 40: died in the decision tree enter the
Page 41 and 42: Administration of apixaban is oral,
Page 43 and 44: A mixed treatment comparison (MTC)
Page 45 and 46: Long term recurrent risks of VTE an
Page 47 and 48: 5.2.7 Health related quality of lif
Page 49 and 50: on assumptions, and not further jus
Page 51 and 52: Table 5.12 Costs for health states
Page 53 and 54: Table 5.14 Drug and administration
Page 55 and 56: Comment - The ERG restructured the
Page 57 and 58: 5.2.10 Sensitivity analyses Methods
Page 59 and 60: Figure 5.3 Cost-effectiveness accep
Page 61: Figure 5.6 Cost-effectiveness accep
Page 65 and 66: Cost-Effectiveness Acceptability Cu
Page 67 and 68: number of QALYs gained by dabigatra
Page 69 and 70: 5.4 Conclusions Describe the comple
Page 71 and 72: References [1] White RH. The epidem
Page 73 and 74: [23] Eriksson BI, Dahl OE, Rosenche
Page 75 and 76: ISPOR 11th Annual European Congress
Page 77 and 78: Appendix 1A: ERG Search Strategies
Page 79 and 80: 85 84 not 83 (88613) 86 1 or 2 or 3
Page 81 and 82: 76 Comment/ (451657) 77 Letter/ (72
Page 83 and 84: 68 Motion Therapy, Continuous Passi
Page 85 and 86: 23 pentasaccharide*.mp. (2192) 24 e
Page 87 and 88: Appendix 1B: Review of search strat
Page 89 and 90: Question(s) Appendix 2: Phillips et
Page 91 and 92: Has the source for all costs been d
show all

Apixaban for the prevention of venous thromboembolism in people ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?